Abbvie (ABBV) Added to BofA/Merrill Lynch US 1 List

BofA/Merrill Lynch analyst Colin Bristow reiterated a Buy rating on Abbvie (NYSE: ABBV), raised his price target to $65.00 (from $60.00) and added the stock to the US 1 List.

Bristow cited increased cost synergy estimates for the ABBV-Shire deal and increased peak sales estimates for ABBV's late-stage Hepatitis C (HCV) regimen.

The firm is raising their cost synergy estimates to 22.5% from the Shire deal, which they said could still understate what is achievable. The firm is increasing peak sales estimates for ABBV’s late-stage HCV regimen (we expect approval in December) to $3.5bn (from $2bn).

The firm raised FY 2015 EPS from $3.77 to 44.20 and FY 2016 EPS from $4.26 to $4.96.

For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.

Shares of Abbvie closed at $54.05 yesterday.

You May Also Be Interested In

• FirstEnergy Corp. (FE) PT Raised to $35 at BofA Securities
• JPMorgan Upgrades Samsung SDS Co Ltd (018260:KS) to Overweight
• Fiserv (FI) PT Raised to $200 at Evercore ISI